Table 3. Clinical characteristics of patients from prospective studies.
| GHS-prospective design | GMS | |
| n = 359 | n = 779 | |
| Males (%) | 242 (67.4) | 397 (50.7) |
| Age (yrs) | 64.5±8.1 | 62.1±9.5 |
| Smokers (%) | 160 (44.5) | 177 (22.6) |
| Diabetes duration (yrs) | 13.8±9.2 | 10.9±9.1 |
| BMI (kg/m2) | 30.2±4.8 | 31.0±5.6 |
| HbA1C(%) | 8.6±1.9 | 8.7±1.9 |
| Glucose-lowering therapy | ||
| Diet only (%) | 23 (6.6) | 107 (13.7) |
| Oral agents (%) | 127 (35.4) | 326 (41.6) |
| Insulin w/wo oral agents (%) | 194 (54.0) | 326 (41.6) |
| Antihypertensive therapy (%) | 305 (85.0) | 405 (51.7) |
| Antidyslipidemic therapy (%) | 233 (64.9) | 261 (33.3) |
| Fibrinogen (mg/dl) | 385.9±124.1 | 365.3±109.6 |
| Resistin (ng/ml) | 10.7±6.6 | 10.1±8.1 |
Continuous variables were reported as mean±SD whereas categorical variables as total frequency and percentages. GHS: Gargano Heart Study; GMS: Gargano Mortality Study; BMI: body mass index; HbA1c: glycated haemoglobin.